Valuation: Ocular Therapeutix, Inc.

Market Cap 2.44B 2.09B 1.95B 1.79B 3.35B 233B 3.4B 23.06B 8.99B 117B 9.15B 8.95B 387B P/E 2026 *
-7.43x
P/E 2027 * -7.95x
Enterprise Value 2.06B 1.76B 1.65B 1.51B 2.83B 197B 2.87B 19.48B 7.6B 98.89B 7.73B 7.56B 327B EV / Sales 2026 *
38.9x
EV / Sales 2027 * 23.1x
Free-Float
99.07%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Ocular Therapeutix, Inc.

1 day-0.09%
1 week+10.36%
Current month+35.62%
1 month+24.08%
3 months+34.79%
6 months+31.75%
Current year-8.73%
1 week 10.3
Extreme 10.3015
11.74
1 month 8.15
Extreme 8.15
11.74
Current year 6.23
Extreme 6.2301
13.03
1 year 6.23
Extreme 6.2301
16.44
3 years 2
Extreme 1.995
16.44
5 years 2
Extreme 1.995
16.44
10 years 2
Extreme 1.995
24.3
Manager TitleAgeSince
Chief Executive Officer 62 15/04/2024
Director of Finance/CFO 50 20/01/2026
Chief Tech/Sci/R&D Officer 49 20/05/2024
Director TitleAgeSince
Chairman 57 01/07/2019
Director/Board Member 78 05/11/2012
Director/Board Member 66 20/03/2019
Date Insider Type Main position Quantity % Market Cap.
23/02/26 Sell

Executive/Senior Manager

1,759 0.0008%
23/02/26 Sell

Executive/Senior Manager

2,810 0.0013%
23/02/26 Sell

Chief Technology Officer

3,057 0.0014%
Change 5-day change 1-year change 3-year change Capi.($)
-0.09%+10.36%-8.66%+183.38% 2.44B
+0.88%+3.84%+77.96%+129.75% 1,109B
+1.07%+3.11%+51.11%+56.67% 644B
+1.20%+5.64%+26.68%+76.48% 463B
+1.02%+3.67%+43.14%+47.27% 371B
+0.85%+2.97%+24.48%+42.54% 301B
+1.26%+4.54%+2.20%+14.84% 256B
+1.88%+5.81%+48.54%+68.52% 234B
+1.59%+0.87%-12.95%-51.91% 205B
+1.87%+5.61%+25.81%+92.42% 178B
Average +1.03%+3.68%+27.83%+65.99% 376.35B
Weighted average by Cap. +1.06%+3.26%+44.90%+72.35%

Financials

2026 *2027 *
Net sales 52.93M 45.34M 42.42M 38.83M 72.88M 5.06B 73.84M 501M 195M 2.54B 199M 194M 8.41B 102M 87.78M 82.14M 75.19M 141M 9.8B 143M 970M 378M 4.93B 385M 376M 16.29B
Net income -334M -286M -268M -245M -460M -31.99B -466M -3.17B -1.23B -16.07B -1.26B -1.23B -53.15B -324M -278M -260M -238M -447M -31.04B -453M -3.07B -1.2B -15.59B -1.22B -1.19B -51.57B
Net Debt -378M -324M -303M -277M -520M -36.17B -527M -3.58B -1.4B -18.17B -1.42B -1.39B -60.09B -66M -56.54M -52.9M -48.42M -90.88M -6.31B -92.08M -625M -244M -3.17B -248M -242M -10.49B
Logo Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company. AXPAXLI, also known as OTX-TKI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases.
Employees
325
Date Price Change Volume
22/08/26 $11.08 -0.09% 3,051,266
20/08/26 $11.09 -5.46% 3,294,718
19/08/26 $11.73 +6.54% 3,024,296
18/08/26 $11.01 +3.38% 4,582,559
17/08/26 $10.65 +6.08% 11,151,659
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
11.09USD
Average target price
27.09USD
Spread / Average Target
+144.28%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OCUL Stock